Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AVC-203
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : AvenCell Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
ViroCell and AvenCell Announce Retroviral Vector Manufacturing Collaboration
Details : The collaboration with ViroCell will help manufacture CAR-T cell therapy products, including AVC-203, an investigational CD19/CD20 dual-targeted cell therapy for the treatment of B-cell malignancies.
Product Name : AVC-203
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 29, 2025
Lead Product(s) : AVC-203
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : AvenCell Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration